Personal genomics company 23andMe has entered into a definitive agreement to acquire telehealth platform Lemonaid Health, Market Watch reported Oct. 22.
Three things to know:
- Lemonaid Health is expected to be acquired for $400 million, with 25 percent paid in cash and 75 percent paid in 23andMe stock.
- The genomics company plans to expand into telemedicine and prescription drug delivery, according to the report. Anne Wojcicki, CEO of 23andMe, said the company will combine providing personal genetic profiles with giving patients and healthcare providers more data on health risks and treatments, Market Watch reported.
- The deal is expected to close by the end of the year.